In an earlier article in The Wire Science, I argued that India’s debate on generic medicines is routinely misframed. The issue is not whether medicines are cheap or expensive, but whether they meet defined standards of quality. Price is a market outcome; quality is a regulatory determination.
That distinction remains central, and it is worth restating because much of the current discussion continues to conflate the two.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
